List view / Grid view
Over the last few years, biologics have continued to make up an increasing proportion of biopharmaceutical sales and pipeline candidates. Cory E Muraco and Wayne Way discuss current trends in biologics analysis.
Medicines are heavily regulated during development, manufacture and distribution.
As the partner of choice for managing microbial quality control, Charles River’s products and services facilitate confident and objective decision-making, ensuring the integrity of your microbial data, reducing risk, building efficiency and improving your bottom line, while assisting in the journey to bring products to market.
Specialising in chromogenic and turbidimetric reagent technologies, Associates of Cape Cod, Inc.
Eurofins PSS Insourcing Solutions® (PSS) employs and manages full-time scientists, managers and support staff to perform a defined scope of work at a client’s facility.
Janssen has recently received marketing authorisation from the European Commission for Stelara to treat ulcerative colitis. Dr Jaime Oliver discusses the mode of action and why the treatment is needed.
At Lonza Pharma & Biotech we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need.
In this Guide to Outsourcing, four companies showcase their services and highlight how they stand out from the crowd. Also included is a discussion of the opportunities that outsourcing presents.
Included in this in-depth focus are articles on using vitamins and fatty acids as APIs as well as the trends that have influenced the global excipients market.
In this in-depth focus are articles on consistent analytical techniques when changing laboratories and using chromatographic techniques to identify impurities in radiopharmaceuticals.
The articles in this in-depth focus explain how microbial contamination in pharmaceutical facilities can occur and discuss the impacts of temperature fluctuations on protein aggregation.
In this in-depth focus are articles exploring the global situation for drug packaging serialisation as well as an assessment of using drones to deliver medicines and how this impacts safety and quality.
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
According to research from the Indian Pharmaceutical Alliance, the country’s pharma sector has capacity to grow. This article investigates some of the goals, challenges and proposals the report sets out for the industry.
Within this issue is an analysis of the impacts that low temperature can have on protein aggregation, a discussion on maintaining the safety and quality of medicines when delivered using drones and an exploration of chromatographic techniques used to identify impurities in radiopharmaceuticals. Other articles focus on regulatory non-compliance, excipients…
